Kerusso Capital Management LLC Boosts Stock Holdings in Bristol Myers Squibb Company $BMY

Kerusso Capital Management LLC boosted its position in Bristol Myers Squibb Company (NYSE:BMY) by 23.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 67,527 shares of the biopharmaceutical company’s stock after purchasing an additional 12,988 shares during the period. Kerusso Capital Management LLC’s holdings in Bristol Myers Squibb were worth $3,642,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of BMY. Man Group plc lifted its stake in Bristol Myers Squibb by 280.4% in the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after purchasing an additional 5,503,391 shares during the last quarter. Two Sigma Investments LP lifted its stake in Bristol Myers Squibb by 530.6% in the third quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock valued at $245,946,000 after purchasing an additional 4,588,601 shares during the last quarter. Van ECK Associates Corp raised its holdings in Bristol Myers Squibb by 67.8% during the 3rd quarter. Van ECK Associates Corp now owns 9,859,915 shares of the biopharmaceutical company’s stock valued at $444,682,000 after acquiring an additional 3,982,439 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Bristol Myers Squibb by 31.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 14,833,977 shares of the biopharmaceutical company’s stock valued at $669,012,000 after acquiring an additional 3,522,696 shares during the period. Finally, AQR Capital Management LLC raised its holdings in Bristol Myers Squibb by 56.0% during the 3rd quarter. AQR Capital Management LLC now owns 9,463,981 shares of the biopharmaceutical company’s stock valued at $426,352,000 after acquiring an additional 3,396,041 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Morgan Stanley reissued an “underweight” rating and set a $40.00 target price on shares of Bristol Myers Squibb in a report on Friday, February 6th. Guggenheim reissued a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. UBS Group reissued a “buy” rating and set a $70.00 target price on shares of Bristol Myers Squibb in a report on Friday, March 6th. Bank of America lowered their target price on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. Finally, Citigroup boosted their target price on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Eight analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus target price of $61.31.

Bristol Myers Squibb Trading Up 0.4%

Bristol Myers Squibb stock opened at $59.02 on Friday. The stock has a market cap of $120.50 billion, a P/E ratio of 17.11, a PEG ratio of 0.17 and a beta of 0.27. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The firm’s fifty day moving average price is $59.72 and its 200-day moving average price is $53.99. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.28 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.05% of the company’s stock.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays upgraded BMY to a Buy, which can support the stock by drawing investor interest and providing a catalyst for further upside. Read More.
• Positive Sentiment: Atrium Therapeutics announced it earned a $15 million development milestone payment from Bristol Myers Squibb under a global cardiovascular collaboration — a signal that a partnered program has hit a development milestone, de‑risking part of BMY’s external pipeline (though it represents a cash outflow). Read More.
• Positive Sentiment: Positive coverage pieces highlighting BMY as a momentum/long‑term holding can attract buy‑and‑hold investors and support multiple expansion. Read More.
• Neutral Sentiment: BMY is a counterparty on a corporate PPA: a new solar project will supply power through previously signed PPAs that include Bristol Myers Squibb — a modest ESG/operational positive but unlikely to move the stock materially. Read More.
• Neutral Sentiment: Industry market reports (vulvar cancer, Sjögren’s syndrome) mention Bristol Myers Squibb among major players — useful context on addressable markets but not an immediate stock driver. Read More. | Read More.
• Neutral Sentiment: Bristol Myers Squibb is expected to report quarterly earnings this week — the timing itself is a catalyst but the direction depends on results and guidance. Read More.
• Negative Sentiment: Analyst previews from Yahoo/Zacks flag that BMY currently lacks the “right combination” of factors (revenue mix and margin tailwinds) that typically produce an earnings beat; consensus calls for a decline in EPS, heightening the risk of a negative market reaction if results disappoint. Read More.
• Negative Sentiment: Bernstein maintained a Hold on BMY, a cautious stance that can cap upside from upgrades and keeps some investors sidelined. Read More.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.